Cabaletta Bio has announced significant progress in its development of chimeric autoantibody receptor T cell (CAAR-T) therapies, marking a major milestone with the initiation of its first pivotal myositis trial and the clearance of a revolutionary automated manufacturing process.
Streamlined Pivotal Trial Design
According to Market Beat, the company has begun enrolling patients in a pivotal myositis study designed as a single-arm trial with 17 participants. Chief Medical Officer David Chang explained that the trial compares patient response rates against a background rate derived from a robust registry database, with approximately five responders needed to achieve statistical significance. The trial composition specifically targets roughly 14 dermatomyositis patients and three antisynthetase syndrome patients, based on Cabaletta’s Phase 1/2 data showing the strongest responses and longest durability in dermatomyositis patients.
The regulatory pathway represents a strategic advantage, as Cabaletta has already secured FDA alignment supporting the single-arm approach. Chang noted that the FDA has demonstrated openness to single-arm trials for CAR-T therapies in autoimmune diseases when endpoints are objective and stringent. The trial’s endpoint requirements include patients being off immunomodulatory medications and on low-dose steroids, emphasizing drug-free remission as a key outcome measure—an endpoint the FDA has prioritized due to the chronic toxicity associated with long-term immunosuppression.
Manufacturing Innovation and Scalability
Perhaps more significantly, Cabaletta has secured IND clearance to manufacture its lead candidate, rese-cel, using a fully automated system developed in partnership with Cellares. This system operates with “no human intervention,” representing a fundamental shift in how autologous cell therapies can be produced. CEO Steven Nichtberger characterized this development as comparable to the Model T assembly line revolution, emphasizing the potential to scale production to thousands of patients while reducing manufacturing complexity and enabling sustainable operations.
Safety Profile Supports Outpatient Treatment
The favorable safety profile of rese-cel continues to support clinical advancement. Cabaletta reported that fewer than 30% of patients experienced grade 1 cytokine release syndrome (CRS), with more than 95% experiencing either no CRS or grade 1 CRS. Notably, the company has reported only two cases of immune effector cell-associated neurotoxicity syndrome (ICANS), with no additional events reported over the past year. This improved safety profile enables the possibility of outpatient administration, which Chief Commercial Officer Steve Gavel highlighted as a key commercial differentiator given that autoimmune patients are typically younger and more mobile than traditional CAR-T populations.
Expanded Clinical Programs
Beyond the myositis trial, Cabaletta is exploring rese-cel without preconditioning (which typically involves cyclophosphamide) in pemphigus vulgaris and lupus patients. Early results from pemphigus vulgaris patients treated at 1 million cells/kg showed responses including B-cell depletion and durable clinical outcomes through six months. The company has also initiated a no-preconditioning cohort in lupus patients, potentially offering the advantage of avoiding cyclophosphamide-related cytopenias.
The company expects to deliver multiple Phase 1/2 complete datasets from lupus, scleroderma, and myasthenia gravis trials in the coming months, along with initial data from products manufactured through the automated Cellares system. These developments position Cabaletta as a leader in advancing CAAR-T therapies for B cell–mediated autoimmune diseases.
